Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 18;9:1532. doi: 10.1038/s41467-018-03915-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Vaccine-induced antitumor immunity in vivo. a The hydrogel vaccines accelerated DC maturation (CD11c⁺CD80⁺CD86⁺) in the tumor examined 3 days post treatment. Data represent mean ± s.d. (n = 3). b Flow cytometric examination of the intratumoral infiltration of CD4⁺ and CD8⁺ T cells (gated on CD3⁺ T cells). Data represent mean ± s.d. (n = 3). c Tumor mass-normalized intratumoral infiltration of CD8+ T cells in the recurrent tumors examined 10 days post treatment. The comparison of two groups was followed by Unpaired student’s t-test (two-tailed). ***p < 0.01. Data represent mean ± s.d. (n = 3). d The frequency of Tregs in the recurrent tumors after different treatments examined 10 days post treatment. Data represent mean ± s.d. (n = 3). e The proliferation activity of CD8⁺ T cells in the recurrent tumor examined 10 days post treatment. f The frequency of TNF-α⁺/IFN-γ⁺ CD8⁺ T cells in the recurrent tumors after different treatments examined 3 days post treatment. g Ratios of tumor-infiltrating CD8⁺ T cells vs. Tregs in the recurrent tumor examined 10 day post the first treatment. e–g The significance of the deferences was evaluated by one-way ANOVA. ***p < 0.01. Data represent mean ± s.d. (n = 3)